Charles River Labs stock trades around recent lows as investors weigh 2024 guidance and Discovery segment sale
Published on 07/26/2026 at 09:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Charles River Laboratories International Inc. (ISIN US1591881009) remains a key contract research player for biopharmaceutical development, and Charles River Labs stock is currently trading near the lower end of its recent twelve month range as investors review 2024 guidance and portfolio changes. The company is listed on the New York Stock Exchange, which keeps it in view for global healthcare investors monitoring outsourcing trends in preclinical and laboratory services.
Revenue of about $4.3 billion in 2023
According to the companys published financial information for fiscal 2023, Charles River Laboratories generated annual revenue of roughly $4.3 billion, reflecting its role as a diversified provider of preclinical, research, and manufacturing support services across biopharma, biotechnology, and academic customers. That full year revenue represented high single digit growth compared with the prior year as the company continued to benefit from demand for outsourced research capacity and specialized safety assessment services.
Within this total, the Research Models and Services segment and the Discovery and Safety Assessment segment contributed a large share of revenue, while the Manufacturing Solutions segment provided additional growth through cell and gene therapy support and microbial solutions. In its 2023 reporting, the company also highlighted that adjusted operating margins remained in the mid to high teens, showing the impact of laboratory utilization rates, mix of higher value services, and cost management measures.
Guidance and comparison with prior year results
For 2024, Charles River Laboratories has communicated financial guidance that points to continued but more moderate growth, reflecting customer budgeting and biopharma funding trends. The company has indicated an expectation of low to mid single digit revenue growth in 2024 compared with 2023, alongside adjusted earnings per share that are planned to be broadly in line with or modestly above the previous years adjusted EPS. This outlook suggests management is aiming to balance investment in capacity and scientific capabilities with margin preservation.
In its most recent quarterly report for 2024, Charles River Laboratories reported quarterly revenue in the region of $1.0 billion, which was slightly higher than the comparable period a year earlier, illustrating that demand has remained resilient even as some clients delay or rephase projects. The quarter also showed adjusted EPS that was close to the level seen in the same quarter of 2023, underlining that pricing discipline and mix helped offset inflationary pressures and selective weakness in early stage discovery budgets.
More on Charles River Labs fundamentals
Key figures from recent annual and quarterly reports help investors understand how Charles River Laboratories balances growth, margins, and portfolio changes in the contract research market.
Discovery sale reshapes portfolio mix
Charles River Laboratories has also been reshaping its portfolio by agreeing to divest its Early Discovery business, a transaction designed to sharpen the companys focus on later stage discovery and safety assessment as well as manufacturing support. The Early Discovery unit contributed a mid single digit percentage of overall revenue, and its planned sale reflects managements intention to concentrate capital and leadership attention on areas where it sees stronger long term demand visibility and differentiation.
The sale of the Early Discovery business is expected to modestly reduce reported revenue growth in the near term while potentially improving the overall margin profile, because the disposed activities carried different profitability characteristics compared with the remaining segments. Investors following Charles River Labs stock therefore pay attention to how the company reallocates resources into higher returning services such as regulated safety assessment studies, biologics testing, and manufacturing solutions for complex modalities.
Product and service focus on laboratory models
A central part of the Charles River Laboratories offering is the supply of research models and related services, which underpin many preclinical and discovery programs. The company provides a broad range of laboratory animals, genetically engineered models, and associated breeding and health monitoring services to pharmaceutical, biotechnology, and academic clients worldwide. This business generates recurring revenue, as customers rely on consistent model quality and biosecurity to support reproducible early stage research.
Beyond physical models, Charles River Laboratories also offers discovery services, safety assessment studies, and manufacturing support for advanced therapies, leveraging its network of facilities and scientific expertise. This integrated approach allows clients to outsource significant parts of the preclinical and early development value chain, which can reduce internal fixed costs and accelerate time to key development milestones.
Charles River Labs stock and market positioning
On the equity market, Charles River Labs stock is associated with the broader healthcare services and contract research organization space, where investors compare it with peers based on growth, margin stability, and balance sheet flexibility. As of a recent trading day in 2024, the companys shares traded at a level that values the business in the mid single digit billions of dollars in terms of market capitalization, placing it among the significant but not mega cap healthcare services names on the New York Stock Exchange.
The share price remains below the peak levels reached during periods of very strong biopharma funding, but above the lows seen during times of more acute market stress. This positioning reflects a balance between concerns about near term funding cycles for smaller biotechnology clients and recognition of the structural trend toward outsourcing preclinical and specialized laboratory work. For long term oriented investors, the evolution of revenue growth from the roughly $4.3 billion level in 2023, the trajectory of margins, and the impact of portfolio moves such as the Early Discovery sale are likely to remain central points of analysis.
Key data for Charles River Labs
- Company: Charles River Laboratories International Inc.
- ISIN: US1591881009
- Ticker: NYSE: CRL
- Trading venue: NYSE
- Sector / Industry: Health Care / Life Sciences Tools & Services
- Index membership: S&P 500
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
